Comparison of Clinical Outcomes of IVUS -Guided and Angiography-guided PCI in Patients With Acute STEMI
Study Details
Study Description
Brief Summary
To compare the long-term clinical outcomes of IVUS-guided vs angiography-guided PCI in patients with acute STEMI
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
This study is a prospective, multicenter, randomized controlled trial, led by the second hospital affiliated to zhejiang university school of medicine, A total of 10 hospitals in zhejiang province interventional cardiovascular center to participate in, plan to recruit 200 STEMI patients.
Subjects according to the proportion of 1:1 were randomly allocated to two treatment groups.(Experimental group (IVUS) steering group or control group (imaging) steering group.) Plan 10 centers in 200 men and women aged 18 and older patients, according to the American heart association and the United States The college of cardiology interventional treatment guidelines for the participants.
Each center recruiting number does not exceed 40% of the total plan recruitment.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Intravascular Ultrasound (IVUS) -guided Primary Percutaneous Intervention (PCI) Intravascular ultrasound guided surgery |
Procedure: Intravascular Ultrasound (IVUS) -guided Primary Percutaneous Intervention (PCI)
Preoperative criminal vascular assessment； The criminal vascular assessment after surgery
Other Names:
|
| No Intervention: Angiography-Guided Primary Percutaneous Intervention (PCI) Angiography-Guided guided surgery |
Outcome Measures
Primary Outcome Measures
- MACE rate at 12 months [up to 12 months]
major adverse cardiac event (MACE) rate at 12 months
- Recurrence of myocardial infarction(including : Myocardialinfarction, Q-wave and non-Q-wave )at 12 months [up to 12 months]
defined as cardiac death, myocardial infarction at 12 months
- TVR(Target Vessel Revascularization) at 12 months [up to 12 months]
defined as cardiac death, myocardial infarction at 12 months
Secondary Outcome Measures
- Major Adverse Cardiovascular Events(2-3 years annual assessment) [3 years]
MACE(including:Recurrence of angina pectoris, Acute Myocardial Infarction, Severe Arrhythmia, Heart Failure, Coronary Heart Disease Death )
- TLR(3 years to evaluate each year) [3 years]
TLR=Target Lesion Reascularization
- TLF(3 years to evaluate each year) [3 years]
TLF=Target Lesion Failure
- TVR(3 years to evaluate each year) [3 years]
TVR=Target Vessels Reascularization
- TVF(3 years to evaluate each year) [3 years]
TVF=Target Vessels Failure
- MI (including:Q-wave and non-Q-wave) [3 years]
Myocardialinfarction, Q-wave and non-Q-wave
- All-cause death [3 years]
All-cause death (including: cardiac and non cardiac)
- Stent thrombosis [3 years]
Stent Thrombosis (including:Sure/May stent thrombosis)
Eligibility Criteria
Criteria
Inclusion Criteria:
-Clinical Inclusion (CI) Criteria: CI. Age > 18 years C2. Onset of STEMI > 30 minutes, but < 12 hours C3. ST segment elevation in at least 2 contiguous leads of≥ 1mm or newly developed LBBB on ECG C4. Willing and able to provide informed consent
-
Angiographic Inclusion (AI) Criteria (visual estimate) AI1. Having at least one infarct-related coronary artery of which
-
the Culprit lesion is suitable for stenting
-
the reference diameter of culprit vessel is ≥ 2.5 mm but ≤ 4 mm
-
the TIMI flow is ≤ 1 in culprit lesion segment prior to guide wire crossing AI2. No excessive tortuosity and calcification in the culprit lesion segment that allowing stent implantation
Exclusion Criteria:
-
Clinical Exclusion (CE) Criteria CE1. Contraindicating to any concomitant study medications CE2. Having cardiogenic shock with hemodynamic instability CE3. A history of bleeding diathesis or known coagulopathy CE4. A history of cerebrovascular accident (CVA) or transient ischemic attack (TIA) within the past 6 months; or a history of intracranial tumor, aneurysm or arteriovenous malformations; or a history of active peptic ulcer or active gastrointestinal (GI) bleeding within the past 2 months; or planned major procedure within 6 weeks; or known platelet count < 100,000 /mm3 or Hb < 10 g/dL CE5. Planned surgery which may cause discontinuation of ADP-receptor antagonist CE6. Other serious illness (e.g., cancer) that may reduce life expectancy to less than 1 year CE7. Repeated MI within 7 days of hospitalization for acute MI
-
Angiographic Exclusion (AE) Criteria (visual estimate) AE1. Bifurcated lesion unable to identify the culprit lesion AE2. The culprit lesion is located in the left main artery. AE3. Diffusive lesions without distinguishable culprit lesion AE4. Previous stent implantation in the culprit lesion segment or STEMI caused by stent thrombosis AE5. Likely CABG procedure within 30 days
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | 2nd Affiliated Hospital, School of Medicine at Zhejiang University | Hangzhou | Zhejiang | China | 310009 |
Sponsors and Collaborators
- Second Affiliated Hospital, School of Medicine, Zhejiang University
- Zhejiang University
- The Second People's Hospital of Hangzhou City in Zhejiang Province
- The First People's Hospital of Tongxiang City in Zhejiang Province
- The People's Hospital of Quzhou City in Zhejiang Province
- The First People's Hospital of Ningbo City in Zhejiang Province
- First Affiliated Hospital of Wenzhou Medical University
- Zhejiang Province People's Hospital
- Taizhou First People's Hospital
- The Central Hospital of Huzhou City in Zhejiang Province
- The People's Hospital of Changxing City in Zhejiang Province
Investigators
- Principal Investigator: Jianan Wang, Second Affiliated Hospital, School of Medicine, Zhejiang University
Study Documents (Full-Text)
More Information
Publications
None provided.- clinical 2020-401